



aProspective observational Cohort study to assess the impact of Biologics on health related quality of life in autoimmune diseases

Engy Waly¹, Rowaida Abdelkader², Mohamed Ahmed AbdelAziz Hussein³, Mohamed Gamal Abd-Raboh³, Enas Abdelaziz¹.

¹Alexandria main university hospital, Alexandria, Egypt, Nasr City Health Insurance Hospital, Egypt,
³Faculty of Medicine Alexandria university, Alexandria, Egypt.

Volume 6, Issue 3, Mar 2024

Received: 15 Nov 2023

Accepted: 15 Jan 2023

Published: 05 Mar 2024

[doi: 10.48047/AFJBS.6.3.2024.832-845](https://doi.org/10.48047/AFJBS.6.3.2024.832-845)

ABSTRACT

Objective : Objective: To assess and compare the impact of biologic agents used to treat rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), and other autoimmune diseases on different domains of health-related quality of life—physical, psychological, mental, and social aspects of well-being that are influenced by disease.

Design : A prospective observational cohort study assessed the effect of biologic therapy on HRQOL for patients in Alexandria Main University Hospital, Alexandria, Egypt. It was conducted between December 2020 and August 2021. The drugs tested were Adalimumab-atto (Amjevita), a monoclonal anti-tumor necrosis factor alpha; Secukinumab (cosentyx), a monoclonal antibody to interleukin-17A; and Etanercept (Enbrel), a tumor necrosis factor (TNF) blocker. Adalimumab (humira) tumor necrosis factor (TNF) blockers, Infliximab (remicade) tumor necrosis factor (TNF)-alpha blockers, and Golimumab (simponi) tumor necrosis factor (TNF) inhibitors. Patient-reported outcomes on 70 participants were done using the validated Arabic version of the SF-36 questionnaire in the form of an oral interview to assess physical, social functioning, role limitations, emotional state, and general health.

Results: Patient outcomes for biologics on the 8 domains of the Short-Form questionnaire SF-36 are expressed by mean +/- SD; for physical functioning is 49.03 +/- 28.31 and median is 45, for role limitation due to physical health is 41.07 ± 39.02 and median is 25, for role limitation due to emotional problems is 51.43 ± 42.73 and median is 66.7, for energy/fatigue is 41.43 ± 16.94 and median is 45, for emotional wellbeing is 48.17 ± 18.20 and median is 52, for social functioning is 55.16 ± 24.86 and median is 62.5, for pain is 55.93 ± 21.56 and median is 55, for general health is 38.74 ± 13.64 and median is 40, for health change is 68.93 ± 25.34 and median is 75.

Conclusion: Infliximab showed significantly better results than Adalimumab and Etanercept regarding physical functioning. Infliximab also established a better outcome in role limitation due to physical health compared to Adalimumab-atto and Adalimumab. Also, Infliximab was significantly better than Adalimumab regarding energy and fatigue. Adalimumab-atto demonstrated a significantly better effect on energy and fatigue than its reference product, Adalimumab.

In rheumatoid arthritis cases, Adalimumab-atto had more favorable outcomes than its reference product, Adalimumab, in terms of energy, fatigue, and emotional well-being. While Etanercept demonstrated better pain management than Adalimumab..

Key word: biologics, autoimmune disease, health-related quality of life, SF36

Q 1: What is already known on this topic?

Biologics individually are known to be effective in improving HRQOL for patients with autoimmune disease.

Q2: What does this study add?

Our study demonstrates a comprehensive comparison between the drugs that help physicians make decisions about choosing between different biologics according to patients' tolerability, compliance, and satisfaction.

Q3: How might this study affect research practice or policy?

As our study compares different biologicals regarding health-related quality of life, we recommend HRQOL assessment be mandatory as routine flow-up work to individualize patients' best therapy according to their needs and satisfaction; moreover, we need more frequent studies with a large sample size.

INTRODUCTION

Many chronic diseases have an impact on patients' quality of life. According to the CDC, HRQoL (health-related quality of life) is defined as “an individual's or a group's perceived physical and mental health over time” (1). Previously, most medical interventions and drug therapy were aimed at prolonging patients' lives. The modern approach also focuses on improving emotional and socioeconomic functioning. (1) Various diseases may not be fatal, but they consume a lot of health care resources and threaten the quality of life of the sufferers. (2)

The ways to assess HRQoL are scores and questionnaires; some are general and others are disease-specific, e.g. DAS-28(3), SF-36(4), and HAQ(5). A short-form questionnaire (SF-36) is an established tool to assess HRQoL in multiple disorders, such as ulcerative colitis. (6) Previously, many of the conventional treatments have failed to improve quality of life and relieve depression and anxiety associated with disease, despite being theoretically effective. The rise of biological therapies has made a huge leap forward in the disease prognosis and therapeutic options available. (7).

Because biologics work on only targeted steps in the inflammatory process instead of attacking the whole immune system, they often have fewer adverse effects than traditional therapies.(8) Biologics such as Adalimumab-atto (Adalimumab-atto), Infliximab (Infliximab), and others are widely used to treat different debilitating diseases such as Rheumatoid arthritis(9,10) , Psoriasis ((11), (12)), Crohn's disease ((13,14), Ulcerative colitis ((15,16), Ankylosing spondylitis, Behcet's disease, and different types of cancer.

MATERIALS AND METHODS

Patients:

This prospective observational cohort study assessed the effect of biologic therapy on HRQOL in patients from different departments in the Governmental Hospital, Alexandria, Egypt. It was conducted between December 2020 and August 2021.

The drugs tested were Adalimumab-atto (Adalimumab-atto), Secukinumab (Secukinumab), Etanercept (Etanercept), Adalimumab (Adalimumab), Infliximab (Infliximab), and Golimumab (Golimumab). Seventy patients were assessed, 54 females and 16 males with ages ranging from 24 to 75 years, using the validated Arabic version of the Short Form Health Survey SF-36 through oral interview to assess 36 items expressing physical and social functioning, role limitations, emotional state, and general health. Inclusion criteria:; exclusion criteria: Questionnaire. Statistical Analysis: Data were fed to the computer and analyzed using IBM SPSS software package version 20.0. (Armonk, NY: IBM Corp.) A descriptive analysis was conducted. Qualitative data were described using numbers and percents. The Kolmogorov-Smirnov test was used to verify the normality of the distribution. Quantitative data were described using range (minimum and maximum), mean, standard deviation, median, and interquartile range (IQR). The significance of the obtained results was judged at the 5% level. The used tests were the Kruskal-Wallis test for abnormally distributed quantitative variables to compare between more than two studied groups and the Post Hoc (Dunn's multiple comparisons test) for pairwise comparisons.

Inclusion criteria: patients on biologic treatment

Exclusion criteria: malignancy patients; pregnancy; ESRD; and end-stage liver disease..

Questionnaire:

The SF-36((17)) is a questionnaire that investigates eight health-related aspects: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Scores resulting from each of the mentioned health-related aspects range from 0 to 100; the higher the score, the better the outcome

Statistical Analysis:

Data were fed to the computer and analyzed using IBM SPSS software package version 20.0. (Armonk, NY: IBM Corp.) A descriptive analysis was conducted. Qualitative data were described using numbers and percents. The Kolmogorov-Smirnov test was used to verify the normality of the distribution. Quantitative data were described using range (minimum and maximum), mean, standard deviation, median, and interquartile range (IQR). The significance of the obtained results was judged at the 5% level.

The used tests were the Kruskal-Wallis test for abnormally distributed quantitative variables to compare between more than two studied groups and the Post Hoc (Dunn's multiple comparisons test) for pairwise comparisons.

RESULTS

Demographic characteristics of study data:

Seventy patients were interviewed; 77.1 percent were female and 22.9 percent were male. The mean age was 42.6 ± 12.8 . Less than one-third suffered from co-morbidities requiring medication, such as hypertension, dyslipidemia, heart failure, and diabetes mellitus. All these conditions were controlled and didn't represent a potential confounding factor for the investigation.

Clinical characteristics of study data:

1- Distribution of the studied cases according to diagnosis in total cases (n = 70)

Rheumatoid arthritis represents 60% of the study population, 28.6% with Crohn's disease, 5.7% with ulcerative colitis, 4.3% with Behcet's, and 1.4% of the patients suffering from ankylosing spondylitis.

2- Distribution of the studied cases according to drug in total cases (n=70)

The drugs' contribution was 31.4% of the patients on Infliximab, 31.4% on Etanercept, 20% on Adalimumab-atto, 14.3% on Adalimumab, 1.4% on Secukinumab, and 1.4% on Golimumab.

3-Relation between drugs and diagnosis (n = 70)

Among 14 patients receiving Adalimumab-atto, 85.7% of them are suffering from rheumatoid arthritis, 7.1% with Behcet's, 7.1% with Crohn's, 22 patients on Etanercept were diagnosed with rheumatoid arthritis, 70% of Adalimumab cases were suffering from rheumatoid arthritis, 20% were Behcet's and 10% were Crohn's, 81.8% of the Infliximab cases were suffering from Crohn's and 18.2% from Ulcerative colitis.

Patient reported impact of biologics on SF-36 domains:

Table (1): Distribution of the studied cases (n = 70) according to different SF-36 domains

	Min. – Max.	Median (IQR)
Physical functioning	0.0 – 100.0	45.0 (30.0 – 75.0)
Role limitation due to physical health	0.0 – 100.0	25.0 (0.0 – 75.0)
Role limitation due to emotional problem	0.0 – 100.0	66.70 (0.0 – 100.0)
Energy/fatigue	10.0 – 80.0	45.0 (30.0 – 50.0)
Emotional well being	4.0 – 84.0	52.0 (32.0 – 64.0)
Social functioning	0.0 – 100.0	62.50(37.50 – 75.0)
Pain	10.0 – 100.0	55.0 (35.0 – 77.50)
General health	10.0 – 65.0	40.0 (30.0 – 50.0)
Health change	0.0 – 100.0	75.0 (50.0 – 75.0)

IQR: Inter quartile range

SD: Standard deviation

Drug-specific impacts on different parameters of HRQoL:**Table (2): Comparisons between drugs and SF36 domains in total cases (n = 70)**

Percent of	Drugs						H	p
	Adalimumab-atto (n = 14)	Cosentyx (n = 1)	Etanercept (n = 22)	Adalimumab (n = 10)	Infliximab (n = 22)	Golimimumab (n = 1)		
Physical functioning								
Min. – Max.	5.0 – 95.0		5.0 – 100.0	2.0 – 100.0	0.0 – 100.0		9.757*	0.021*
Median	37.50	55.0 [#]	40.0	32.50	67.50	40.0 [#]		
Sig. bet. Drugs	p ₁ =0.554,p ₂ =0.550,p ₃ =0.061,p ₄ =0.907,p ₅ =0.005*,p ₆ =0.020*							
Role limitation due to physical health								
Min. – Max.	0.0 – 100.0		0.0 – 100.0	0.0 – 100.0	0.0 – 100.0		10.29*	0.016*
Median	0.0	50.0 [#]	50.0	12.50	75.0	25.0 [#]		
Sig. bet. Drugs	p ₁ =0.095,p ₂ =0.899,p ₃ =0.005*,p ₄ =0.174,p ₅ =0.196,p ₆ =0.017*							
Role limitation due to emotional problem								
Min. – Max.	0.0 – 100.0		0.0 – 100.0	0.0 – 100.0	0.0 – 100.0		4.573	0.206
Median	66.70	100.0 [#]	66.70	0.0	66.70	0.0 [#]		
Energy/fatigue								
Min. – Max.	20.0 – 80.0		10.0 – 80.0	10.0 – 70.0	10.0 – 65.0		8.920*	0.030*
Median	45.0	65.0 [#]	35.0	27.50	47.50	45.0 [#]		
Sig. bet. Drugs	p ₁ =0.062,p ₂ =0.023*,p ₃ =0.861,p ₄ =0.423,p ₅ =0.055,p ₆ =0.020*							
Emotional well being								
Min. – Max.	28.0 – 84.0		24.0 – 80.0	4.0 – 76.0	20.0 – 80.0		6.669	0.083
Median	58.0	56.0 [#]	50.0	32.0	50.0	52.0 [#]		

Percent of	Drugs						H	p
	Adalimumab-atto (n = 14)	Cosentyx (n = 1)	Etanercept (n = 22)	Adalimumab (n = 10)	Remicaide (n = 22)	Golimumab (n = 1)		
Social functioning								
Min. – Max.	25.0 – 100.0		12.50–100.0	0.0 – 87.50	12.50–100.0		4.222	0.238
Median	62.50	75.0 [#]	62.25	37.50	62.50	37.50 [#]		
Pain								
Min. – Max.	10.0 – 100.0		22.50 – 90.0	32.50 – 90.0	20.0 – 100.0		3.114	0.374
Median	55.0	67.5 [#]	55.0	40.0	55.0	55.0 [#]		
General health								
Min. – Max.	20.0 – 55.0		10.0 – 60.0	10.0 – 65.0	15.0 – 60.0		2.272	0.518
Median	45.0	45.0 [#]	40.0	37.50	35.0	40.0 [#]		
Health change								
Min. – Max.	25.0 – 100.0		25.0 – 100.0	50.0 – 100.0	0.0 – 100.0		0.428	0.934
Median	75.0	75.0 [#]	75.0	75.0	75.0	50.0 [#]		

H: H for **Kruskal Wallis test**, Pairwise comparison between each 2 groups was done using **Post Hoc Test (Dunn's for multiple comparisons test)**

P: p value for comparing between the studied drugs

p1: p value for comparing between **Adalimumab-atto** and **Etanercept**

p2: p value for comparing between **Adalimumab-atto** and **Adalimumab**

p3: p value for comparing between **Adalimumab-atto** and **Infliximab**

p4: p value for comparing between **Etanercept** and **Adalimumab**

p5: p value for comparing between **Etanercept** and **Infliximab**

p6: p value for comparing between **Adalimumab** and **Infliximab**

*: Statistically significant at $p \leq 0.05$

#: Excluded from the comparison due to small number of case (n = 1)

Physical functioning:

- There is statistically significant difference between Infliximab and Etanercept, favoring Infliximab and between Adalimumab and Infliximab, favoring Infliximab.

Role limitations due to physical functioning:

- There is statistically significant difference between Infliximab and Adalimumab-atto, favoring Infliximab and between Adalimumab and Infliximab, favoring Infliximab.

Energy/Fatigue:

- There is a statistically significant difference between Adalimumab-atto and Adalimumab, favoring Adalimumab-atto while comparison between Adalimumab and Infliximab, favoring Infliximab(P=0.02).
- In the remaining domains, no statistically significant differences were found.

Impact of drugs on disease specific parameters:

Rheumatoid Arthritis:

- Regarding rheumatoid cases (n=40) in table (3); there is a statistically significant difference between Adalimumab-atto and Adalimumab in energy/fatigue and in emotional well-being, favoring Adalimumab-atto.
- For pain management in table (3); the statistical significant difference between Etanercept and Adalimumab is favoring Etanercept.
- The remaining domains didn't show statistical significant difference among the tested drugs.

Crohn's disease:

Table (4) results are not reliable until availability and investigation of more cases.

Table (3): Comparison between drugs and SF36 domains in rheumatoid cases (n = 41)

Percent of	Drugs			H	p
	Adalimumab-atto (n = 12)	Etanercept (n = 22)	Adalimumab (n = 7)		
Physical functioning					
Min. – Max.	5.0 – 85.0	5.0 – 100.0	2.0 – 35.0	4.565	0.102
Median	35.0	40.0	15.0		
Role limitation due to physical health					
Min. – Max.	0.0 – 75.0	0.0 – 100.0	0.0 – 50.0	5.352	0.069
Median	0.0	50.0	25.0		
Role limitation due to emotional problem					
Min. – Max.	0.0 – 100.0	0.0 – 100.0	0.0 – 100.0	3.225	0.199
Median	50.0	66.70	0.0		
Energy/fatigue					
Min. – Max.	20.0 – 65.0	10.0 – 80.0	10.0 – 45.0	8.847*	0.012*
Median	45.0	35.0	25.0		
Sig. bet. Drugs	p ₁ =0.105,p ₂ =0.003*,p ₃ =0.056				
Emotional well being					
Min. – Max.	28.0 – 84.0	24.0 – 80.0	4.0 – 76.0	6.443*	0.040*
Median	60.0	50.0	32.0		
Sig. bet. Drugs	p ₁ =0.247,p ₂ =0.011*,p ₃ =0.068				

Percent of	Drugs			H	P
	Adalimumab-atto (n = 12)	Etanercept (n = 22)	Adalimumab (n = 7)		
Social functioning					
Min. – Max.	25.0 – 75.0	12.50 – 100.0	0.0 – 75.0	4.912	0.086
Median	62.50	62.25	25.0		
Pain					
Min. – Max.	10.0 – 100.0	22.50 – 90.0	32.50 – 55.0	7.219*	0.027*
Median	55.0	55.0	35.0		
Sig. bet. Drugs	p ₁ =0.272,p ₂ =0.109,p ₃ =0.008*				
General health					
Min. – Max.	20.0 – 55.0	10.0 – 60.0	10.0 – 55.0	0.747	0.688
Median	42.50	40.0	30.0		
Health change					
Min. – Max.	25.0 – 100.0	25.0 – 100.0	50.0 – 100.0	0.028	0.986
Median	75.0	75.0	75.0		

SD: Standard deviation

H: H for **Kruskal Wallis test**, Pairwise comparison between Each 2 groups was done using **Post Hoc Test (Dunn's for multiple comparisons test)**

p: p value for comparing between the studied drugs

p₁: p value for comparing between **Adalimumab-atto** and **Etanercept**

p₂: p value for comparing between **Adalimumab-atto** and **Adalimumab**

p₃: p value for comparing between **Etanercept** and **Adalimumab**

*: Statistically significant at $p \leq 0.05$

\

Table (4): Comparison between drugs and SF36 domains in Crohn's cases (n = 20)

Percent of	Drugs		
	Adalimumab- atto (n = 1) [#]	Adalimumab (n = 1) [#]	Infliximab (n = 18)
Physical functioning			
Min. – Max.			20.0 – 100.0
Median	50.0 [#]	100.0 [#]	62.50
Role limitation due to physical health			
Min. – Max.			0.0 – 100.0
Median	0.0 [#]	100.0 [#]	75.0
Role limitation due to emotional problem			
Min. – Max.			0.0 – 100.0
Median	100.0 [#]	100.0 [#]	66.70
Energy/fatigue			
Min. – Max.			10.0 – 65.0
Median	50.0 [#]	70.0 [#]	50.0
Emotional well being			
Min. – Max.			24.0 – 80.0
Median	44.0 [#]	64.0 [#]	54.0
Social functioning			
Min. – Max.			25.0 – 100.0
Median	62.50 [#]	87.50 [#]	75.0
Pain			
Min. – Max.			20.0 – 100.0
Median	55.0 [#]	90.0 [#]	55.0
General health			
Min. – Max.			15.0 – 60.0
Median	55.0 [#]	55.0 [#]	37.50
Health change			
Min. – Max.			0.0 – 100.0
Median	75.0 [#]	100.0 [#]	75.0

[#]: Excluded from the comparison due to small number of cases (n = 1)

DISCUSSION

The objective of the study was to provide clinical, functional information, and patient reported outcomes in reality settings among studied patients. A strength of our study is the simultaneous investigation of multiple drugs and multiple disorders, the relationships between them, and their impact on QoL. A short time and one study setting are considered study weaknesses. Through the study of 70 patients on biologics and their effect on HRQoL had been studied.

Infliximab proved significantly better results than Adalimumab and Etanercept regarding physical functioning. Infliximab established a better outcome in role limitation due to physical health compared to Adalimumab-atto and Adalimumab. Infliximab was significantly better than Adalimumab regarding energy and fatigue. This may be due to the fact that the majority of patients treated with Infliximab had Crohn's disease, which doesn't affect their physical functioning and health as much as in patients diagnosed with rheumatoid arthritis. So, the disease itself might be a factor. Results from other studies match our findings, as they find Infliximab improves most aspects of HRQoL within 8 weeks of therapy initiation up to 30 weeks of long-term maintenance therapy. ((6,18)) Another hypothesis may be due to the route of administration, as Infliximab was given in health care settings intravenously, which guarantees 100% drug bioavailability and an immediate distribution, while Adalimumab was administered subcutaneously at home which guarantees better compliance ((19))

The benefits of Adalimumab on HRQoL have been proven in multiple studies, as has its positive influence on work productivity. ((20), (21)). Interestingly, Adalimumab-atto demonstrated a significantly better effect on energy and fatigue than its reference product, Adalimumab. The reason for this unexpected result was not exactly known, but perhaps the patient's tolerability of the intrinsic nature of biologics. Biosimilars are products similar to the original drug in the active substance but not exactly the same because of differences in manufacturing details, including methods of purification. (22)

In rheumatoid arthritis cases, Adalimumab-atto had more favorable outcomes than its reference product, Adalimumab, in energy, fatigue, and emotional well-being((23,24). While Etanercept demonstrated better pain management than Adalimumab, this is unlike the results of an indirect comparison done between Etanercept and Adalimumab in the management of psoriasis, where adalimumab treatment for moderate to severe plaque psoriasis was associated with greater pain management, higher rates of resolution of skin signs and symptoms, and greater improvements in dermatological life quality. ((25)) In Crohn's cases, the results were unreliable. The superiority of one drug over another cannot be established until more patients are interviewed and more results are obtained.

Conclusion:

Infliximab showed better results than Adalimumab and Etanercept regarding physical functioning. Infliximab also established a better outcome in role limitation due to physical health compared to Adalimumab-atto and Adalimumab. Infliximab was significantly better than Adalimumab regarding energy and fatigue. Further research with a larger sample size will be needed to determine whether these results are disease-related or due to the drug itself. Adalimumab-atto demonstrated a significantly better effect on energy and fatigue than its reference product, Adalimumab, especially in rheumatoid arthritis cases, in addition to its effect on emotional well-being. Therefore, Adalimumab-atto may be better for depressed

patients. While Etanercept demonstrated better pain management than Adalimumab, suggesting it is a suitable option for patients with pain.

REFERENCES

1. Yin S, Njai R, Barker L, Siegel PZ, Liao Y. Summarizing health-related quality of life (HRQOL): development and testing of a one-factor model. *Popul Health Metr.* 2016 Jul 11;14:22. doi: 10.1186/s12963-016-0091-3. PMID: 27408606; PMCID: PMC4940947.
2. Lam, C. L., & Lauder, I. J. (2000). *The impact of chronic diseases on the health-related quality of life (HRQOL) of Chinese patients in primary care.* *Family Practice*, 17(2), 159–166. doi:10.1093/fampra/17.2.159
3. Han R, Ren HC, Zhou S, Gu S, Gu YY, Sze DM, Chen MH. Conventional disease-modifying anti-rheumatic drugs combined with Chinese Herbal Medicines for rheumatoid arthritis: A systematic review and meta-analysis. *J Tradit Complement Med.* 2022 Jan 26;12(5):437-446. doi: 10.1016/j.jtcme.2022.01.005. PMID: 36081815; PMCID: PMC9446108.
4. Lins L, Carvalho FM. SF-36 total score as a single measure of health-related quality of life: Scoping review. *SAGE Open Med.* 2016 Oct 4;4:2050312116671725. doi: 10.1177/2050312116671725. PMID: 27757230; PMCID: PMC5052926.
5. Pincus T, Swearingen CJ. The HAQ compared with the MDHAQ: "keep it simple, stupid" (KISS), with feasibility and clinical value as primary criteria for patient questionnaires in usual clinical care. *Rheum Dis Clin North Am.* 2009 Nov;35(4):787-98, ix. doi: 10.1016/j.rdc.2009.10.011. PMID: 19962623.
6. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med.* 2005 Dec 8;353(23):2462-76. doi: 10.1056/NEJMoa050516. Erratum in: *N Engl J Med.* 2006 May 18;354(20):2200. PMID: 16339095.
7. Iskandar IYK, Ashcroft DM, Warren RB, Lunt M, McElhone K, Smith CH, Reynolds NJ, Griffiths CEM. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. *Br J Dermatol.* 2017 Nov;177(5):1410-1421. doi: 10.1111/bjd.15531. Epub 2017 Oct 19. PMID: 28369707; PMCID: PMC6487951.
8. Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. *Clin Exp Gastroenterol.* 2009;2:101-9. doi: 10.2147/ceg.s4512. Epub 2009 Sep 25. PMID: 21694833; PMCID: PMC3108643.
9. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol.* 2016 Jan;68(1):1-26. doi: 10.1002/art.39480. Epub 2015 Nov 6. PMID: 26545940.
10. Yayikci YI, Karadag A. Effects of conventional and biological drugs used for the treatment of rheumatoid arthritis on the quality of life and depression. *Eurasian Journal of Medicine.* 2019 Feb 1; 51(1):12–6.
11. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J. Special

- Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis Rheumatol.* 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. Epub 2018 Nov 30. PMID: 30499246; PMCID: PMC8218333.
- 12 Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol.* 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13. PMID: 30772098.
 - 13 Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts P, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. *Gut.* 2009; 58(7):940–8.
 - 14 Macaluso FS, Papi C, Orlando A, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD); Working panel; Review panel. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology. *Dig Liver Dis.* 2023 Apr;55(4):442-453. doi: 10.1016/j.dld.2023.01.155. Epub 2023 Feb 13. PMID: 36792429.
 - 15 Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S, Gerson L, et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. *Gastroenterology.* 2017 Sep 1; 153(3):827–34.
 16. Côté-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P. Biologics in inflammatory bowel disease: what are the data? *United European Gastroenterol J.* 2015 Oct;3(5):419-28. doi: 10.1177/2050640615590302. PMID: 26535119; PMCID: PMC4625751.
 - 17 .Burholt V, Nash P. Short Form 36 (SF-36) Health Survey Questionnaire: normative data for Wales. *J Public Health (Bangkok)* [Internet]. 2011 Dec 1 [cited 2021 Aug 3]; 33(4):587–603.
Available from: <https://academic.oup.com/jpubhealth/article/33/4/587/1565751>
 18. Paschos P, Katsoula A, Salanti G, Giouleme O, Athanasiadou E, Tsapas A. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. *Aliment Pharmacol Ther.* 2018 Dec;48(11-12):1174-1185. doi: 10.1111/apt.15005. Epub 2018 Oct 30. PMID: 30378141.
 19. Franca R, Curci D, Lucafò M, Decorti G, Stocco G. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. *Expert Opin Drug Metab Toxicol.* 2019 Jul;15(7):527-539. doi: 10.1080/17425255.2019.1630378. Epub 2019 Jun 14. PMID: 31177858.
 20. Barreiro M, Romero P, Pereira S, Xeral Cíes H, Jesús Puente J, Alto Guadalquivir H pital, et al. On behalf of the EFICADEC researchers group: Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumab. *Rev esp enferM dig.* 2017; 109(2):122–9.
 - 21 Travis S, Feagan BG, Peyrin-Biroulet L, Panaccione R, Danese S, Lazar A, et al. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a

- Clinical Practice Setting: Results From InspirADA. J Crohns Colitis [Internet]. 2017 Nov 1 [cited 2022 Oct 11]; 11(11):1317. Available from: /pmc/articles/PMC5881702/
22. Kirchoff CF, Wang XM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: Key regulatory considerations and similarity assessment tools. *Biotechnol Bioeng*. 2017 Dec;114(12):2696-2705. doi: 10.1002/bit.26438. Epub 2017 Sep 19. PMID: 28842986; PMCID: PMC5698755.
 23. Zhao S, Chadwick L, Mysler E, Moots RJ. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis. *Curr Rheumatol Rep*. 2018 Aug 9;20(10):57. doi: 10.1007/s11926-018-0769-6. PMID: 30094742; PMCID: PMC6097048.
 24. Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. *J Rheumatol*. 2012 Jan;39(1):63-72. doi: 10.3899/jrheum.101161. Epub 2011 Nov 1. PMID: 22045836.
 25. Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, et al. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials. *Value in Health*. 2018; 21(1):1-8.